Outcomes of adults with restrictive cardiomyopathy after heart transplantation

JOURNAL OF HEART AND LUNG TRANSPLANTATION

卷:31

Article

DePasquale, Eugene C.²  Nasir, Khurram¹  Jacoby, Daniel L.¹ 

[1] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06510 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA

关键词: amyloid;    chemotherapy-induced cardiomyopathy;    heart transplantation;    outcomes;    radiation-induced cardiomyopathy;    restrictive cardiomyopathy;   

DOI  :  10.1016/j.healun.2012.09.018

来源: Elsevier

【 摘 要 】

BACKGROUND: Restrictive cardiomyopathy (RCM) represents a spectrum of disorders with a common physiology but divergent etiologies. RCM commonly leads to progressive heart failure and the need for heart transplantation (HTx). Pediatric RCM is a more homogeneous disorder with post-HTx outcomes comparable to those for non-RCM patients. However, post-HTx outcomes in adult RCM patients have not been studied to date. METHODS: Demographic, clinical and survival outcomes of 38,190 adult HTx-only recipients from 1987 to 2010 were acquired from the registry of the United Network of Organ Sharing. The study population included 544 RCM patients (1.4%) and 37,646 non-RCM patients (98.6%). RCM diagnoses included idiopathic (n = 227, 42%), amyloid (n = 142, 26%), sarcoid (n = 81, 15%), radiation/chemotherapy (XRT) (n = 35, 6%) and other (n = 59, 11%). RESULTS: Follow-up began at the time of HTx (74 +/- 64 months). During the follow-up period, 224 (41%) patients in the RCM group died, whereas 18,791 (50%) in the non-RCM group died. Crude 1-, 5- and 10-year survival for RCM patients was 84%, 66% and 45%, and for non-RCM patients was 85%, 70% and 50%, respectively. The overall unadjusted hazard ratio of RCM vs non-RCM for all-cause mortality was 1.07 (confidence interval [CI] 0.93 to 1.22). Multivariate Cox proportional hazards regression analysis yielded a hazard ratio of 1.06 (Cl 0.91 to 1.25). RCM subgroup analysis showed decreased survival at 1, 5 and 10 years in the XRT (71%, 47% and 32%) and amyloid (79%, 47% and 28%) patient groups. The unadjusted hazard ratio for the XRT and amyloid subgroups vs RCM for all-cause mortality was 1.81 (p = 0.002) and 1.85 (p = 0.0004), respectively. CONCLUSIONS: Outcomes for RCM patients post-HTx are comparable to those of non-RCM patients. However, RCM subgroup analysis suggests increased mortality for XRT and emyloid subgroups. Further analysis is warranted to understand the contributing factors. J Heart Lung Transplant 2012; 31: 1269-75 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.

【 授权许可】

Free